Physician profile
Cary O Harding
NPI 1952327926
$215,407.01
in general payments reported to CMS, 2019-2025
6 companies · $53K in 2025
The $53K reported for 2025 was more than what 94% of Clinical Genetics (M.D.) providers received nationally (typical 2025 total: $255).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $30K · 2021: $12K · 2022: $18K · 2023: $15K · 2024: $50K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $54K · Consulting Fee: $51K · Travel and Lodging: $13K · Food and Beverage: $1,168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,868.97 |
| Consulting Fee | $50,588.67 |
| Travel and Lodging | $13,063.44 |
| Food and Beverage | $1,168.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $181,670.46 | 2019-2025 | Palynziq |
| Sanofi US Services INC. | $12,240.00 | 2021-2023 | |
| Ultragenyx Pharmaceutical INC. | $9,529.51 | 2019-2025 | |
| Ptc Therapeutics, INC. | $6,740.42 | 2022-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $5,226.62 | 2024-2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.